Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE SR versus BRONKOMETER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE SR versus BRONKOMETER.
AEROLATE SR vs BRONKOMETER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (cAMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
None Documented
None Documented
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator